Table 4 Contingency tables showing the association between deterioration on each scale and the occurrence of grade 2 £ treatment-related adverse events.

From: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors

Questionnaire

Domains and functions

(abbreviation)

Change during ICI therapy

Total

Grade 2 ≤ adverse events

Odds ratio

(95% confidence interval)

Fisher’s exact test

P value

No

Yes

Total

42

19

23

  

EORTC QLQ-C30

Global health status/QoL

Improved/stable

30

16

14

  
  

Deteriorated

12

3

9

3.5 (0.77–12.2)

0.17

 

Physical functioning (PF)

Improved/stable

29

15

14

  
  

Deteriorated

13

4

9

2.4 (0.61–8.2)

0.32

 

Role functioning (RF)

Improved/stable

27

13

14

  
  

Deteriorated

15

6

9

1.4 (0.40–4.5)

0.75

 

Emotional functioning (EF)

Improved/stable

33

15

18

  
  

Deteriorated

9

4

5

1.0 (0.23–3.9)

0.99

 

Cognitive functioning (CF)

Improved/stable

25

13

12

  
  

Deteriorated

17

6

11

2.0 (0.60–6.3)

0.35

 

Social functioning (SF)

Improved/stable

27

12

15

  
  

Deteriorated

15

7

8

0.91 (0.26–3.4)

0.99

FACT-G

Physical well-being (PWB)

Improved/stable

28

13

15

  
  

Deteriorated

14

6

8

1.2 (0.31–3.8)

0.99

 

Social/family well-being (SWB)

Improved/stable

20

7

13

  
  

Deteriorated

22

12

10

0.45 (0.12–1.4)

0.23

 

Emotional well-being (EWB)

Improved/stable

27

14

13

  
  

Deteriorated

15

5

10

2.1 (0.61–7.7)

0.34

 

Functional well-being (FWB)

Improved/stable

27

12

15

  
  

Deteriorated

15

7

8

0.91 (0.26–3.4)

0.99

 

FACT-G total score

Improved/stable

28

12

16

  
  

Deteriorated

14

7

7

0.75 (0.19–2.9)

0.75

SF-8

Physical function (PF)

Improved/stable

32

18

14

  
  

Deteriorated

10

1

9

11.6 (1.7–133)

0.013

 

Role physical (RP)

Improved/stable

30

16

14

  
  

Deteriorated

12

3

9

3.4 (0.77–13.2)

0.17

 

Bodily pain (BP)

Improved/stable

24

12

12

  
  

Deteriorated

18

7

11

1.6 (0.49–5.7)

0.54

 

General health (GH)

Improved/stable

28

14

15

  
  

Deteriorated

14

6

8

1.2 (0.35–4.1)

0.99

 

Vitality (VT)

Improved/stable

25

12

13

  
  

Deteriorated

17

7

10

1.3 (0.40–4.8)

0.76

 

Social functioning (SF)

Improved/stable

31

15

16

  
  

Deteriorated

11

4

7

1.6 (0.36–5.8)

0.73

 

Role emotional (RE)

Improved/stable

30

14

16

  
  

Deteriorated

12

5

7

1.2 (0.29–4.6)

0.99

 

Mental health (MH)

Improved/stable

30

14

16

  
  

Deteriorated

12

5

7

1.2 (0.29–4.6)

0.99

 

Physical component summary (PCS)

Improved/stable

27

14

13

  
  

Deteriorated

15

5

10

2.2 (0.61–7.7)

0.34

 

Mental component summary (MCS)

Improved/stable

26

12

14

  
  

Deteriorated

16

7

9

1.1 (0.32–4.1)

0.17

  1. ICI immune checkpoint inhibittor, EORTC QLQ-C30 the European organization for research and treatment of cancer quality of life questionnaire - core 30, FACT-G functional assessment of cancer therapy-general, SF-8 8-item short form survey.
Back to article page